Bio-Thera Solutions, Ltd.,

POBEVCY® Bevacizumab（100mg/4mL）

Please take it under the guidance of experienced pharmacist.

BAT1706 (Avzivi®, bevacizumab) is a humanized monoclonal antibody that targets VEGF. It specifically binds to VEGF and blocks the binding of VEGF to its receptor, thereby reducing neovascularization, inducing the degradation of existing blood vessels, and thereby inhibiting tumor growth. The brand name for BAT1706 in the EU and the United States is Avzivi®.

Prescribing Information

POBEVCY®

Indications

In the United States, Avzivi® is indicated for the treatment of 1) Metastatic colorectal cancer, 2) non-squamous non-small cell lung cancer, 3) glioblastoma in adults, 4) Metastatic renal cell carcinoma, 5) cervical cancer, 6) Epithelial ovarian, fallopian tube, or primary peritoneal cancer. In the Europe, Avzivi® is indicated for the treatment of 1) Metastatic carcinoma of the colon or rectum, 2) Metastatic breast cancer, 3) non-small cell lung cancer, 4) renal cell cancer, 5) epithelial ovarian, fallopian tube, or primary peritoneal cancer, 6) carcinoma of the cervix.

POBEVCY® Bevacizumab（100mg/4mL）

Please take it under the guidance of experienced pharmacist.

Indications